ArticleInfection and drug resistance2025
Emerging Insights into
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Materials and Methods: This retrospective study was conducted at Hamad Medical Corporation, Qatar, including all CKC isolates from breast tissue collected between October 2016 and March 2024. Data from electronic medical records were collected and anonymized. Microbiological analysis involved standard culture techniques, Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) for identification, and antibiotic susceptibility testing per Clinical and Laboratory Standards Institute (CLSI) standards. Statistical methods included descriptive analyses, Pearson's correlation, and relative risk calculations. Results: Among 34 isolates, 31 were from breast tissue of pre-menopausal women, predominantly obese or overweight, with a median age of 33 years. Breast abscesses were typically unilateral, associated with axillary lymphadenopathy, and varied in size and complexity. Recurrence within six months occurred in 58% of cases. Prolonged antimicrobial therapy and, in some cases, surgical intervention were necessary. Most isolates were sensitive to vancomycin, linezolid, and rifampicin, but resistance to penicillin and daptomycin was noted. Conclusion: CKC is an emerging pathogen in breast abscesses, requiring precise diagnostic approaches and individualized treatment strategies. Advanced genomic tools are recommended for species differentiation and resistance monitoring. Ongoing research is essential to optimize management and address rising antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.